tradingkey.logo

HUTCHMED (China) Ltd

HCM
查看详细走势图
13.550USD
+0.200+1.50%
收盘 12/19, 16:00美东报价延迟15分钟
11.82B总市值
25.06市盈率 TTM

HUTCHMED (China) Ltd

13.550
+0.200+1.50%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.50%

5天

+0.97%

1月

-4.44%

6月

-8.69%

今年开始到现在

-5.97%

1年

-5.31%

查看详细走势图

TradingKey HUTCHMED (China) Ltd股票评分

单位: USD 更新时间: 2025-10-27

操作建议

当前估值低估,机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间,可以做区间波段操作。

HUTCHMED (China) Ltd评分

相关信息

行业排名
135 / 173
全市场排名
552 / 4682
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 12 位分析师
买入
评级
21.215
目标均价
+51.10%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

HUTCHMED (China) Ltd亮点

亮点风险
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
业绩高增长
公司营业收入稳步增长,连续3年增长47.79%
估值低估
公司最新PE估值27.48,处于3年历史低位
机构减仓
最新机构持股6.34M股,环比减少47.27%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值1.17K

HUTCHMED (China) Ltd新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

HUTCHMED (China) Ltd简介

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
公司代码HCM
公司HUTCHMED (China) Ltd
CEOCheng (Chig Fung)
网址https://www.hutch-med.com/

常见问题

HUTCHMED (China) Ltd(HCM)的当前股价是多少?

HUTCHMED (China) Ltd(HCM)的当前股价是 13.550。

HUTCHMED (China) Ltd的股票代码是什么?

HUTCHMED (China) Ltd的股票代码是HCM。

HUTCHMED (China) Ltd股票的52周最高点是多少?

HUTCHMED (China) Ltd股票的52周最高点是19.500。

HUTCHMED (China) Ltd股票的52周最低点是多少?

HUTCHMED (China) Ltd股票的52周最低点是11.505。

HUTCHMED (China) Ltd的市值是多少?

HUTCHMED (China) Ltd的市值是11.82B。

HUTCHMED (China) Ltd的净利润是多少?

HUTCHMED (China) Ltd的净利润为37.73M。

现在HUTCHMED (China) Ltd(HCM)的股票是买入、持有还是卖出?

根据分析师评级,HUTCHMED (China) Ltd(HCM)的总体评级为买入,目标价格为21.215。

HUTCHMED (China) Ltd(HCM)股票的每股收益(EPS TTM)是多少

HUTCHMED (China) Ltd(HCM)股票的每股收益(EPS TTM)是0.541。
KeyAI